Drug · FAERS side-effect profile with label screen
Lebrikizumab-Lbkz side effects: what 16 FDA adverse event reports show
Drug class
No validated FDA label found
Who reports
16 reports · 0% serious · 0 with death outcome · 56% female
openFDA FAERS counts, all years, deduplication not applied
Used for
—
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation.
Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)?
That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.
Causality screen of the 36 strongest signals
Reporting / coding artifact 5No label text to screen 31
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 14 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
Show:
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Conjunctivitis | 126 | 76.2 64.3–90.3ROR 81.5 · χ² 9,219 / p <1e-300 | 74.8 EB05 64.5 · IC025 +5.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Dermatitis atopic | 131 | 29.0 24.6–34.2ROR 31.1 · χ² 3,514 / p <1e-300 | 28.8 EB05 24.9 · IC025 +4.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eczema | 108 | 23.7 19.8–28.5ROR 25.1 · χ² 2,331 / p <1e-300 | 23.6 EB05 20.1 · IC025 +4.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Incorrect dose administered by device | 38 | 16.5 12.1–22.7ROR 16.9 · χ² 539 / p 2e-119 | 16.3 EB05 12.3 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Eye pruritus | 43 | 14.4 10.7–19.4ROR 14.7 · χ² 523 / p 4e-116 | 14.2 EB05 10.8 · IC025 +3.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Sleep disorder due to a general medical condition | 19 | 13.0 8.3–20.3ROR 13.1 · χ² 198 / p 3e-45 | 12.2 EB05 7.7 · IC025 +2.5 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin fissures | 21 | 12.3 8.0–18.8ROR 12.4 · χ² 207 / p 4e-47 | 11.5 EB05 7.5 · IC025 +2.5 3/3 methods agree | No label text to screen | – | no trial data cached |
| Ocular hyperaemia | 51 | 12.1 9.2–15.8ROR 12.4 · χ² 507 / p 2e-112 | 11.8 EB05 9.2 · IC025 +3.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eye discharge | 11 | 11.9 6.6–21.4ROR 12.0 · χ² 99 / p 1e-23 | 10.0 EB05 5.3 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site discomfort | 10 | 10.7 5.8–19.9ROR 10.7 · χ² 78 / p 4e-19 | 8.6 EB05 4.5 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin haemorrhage | 11 | 8.4 4.7–15.2ROR 8.5 · χ² 65 / p 4e-16 | 6.7 EB05 3.8 · IC025 +1.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Lacrimation increased | 22 | 8.1 5.4–12.3ROR 8.2 · χ² 131 / p 1e-30 | 7.2 EB05 4.9 · IC025 +2.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Dermatitis | 15 | 8.0 4.8–13.2ROR 8.0 · χ² 85 / p 2e-20 | 6.7 EB05 4.2 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eye irritation | 39 | 7.7 5.7–10.5ROR 7.9 · χ² 222 / p 2e-50 | 7.2 EB05 5.5 · IC025 +2.3 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site pain (pain where injected) | 207 | 7.5 6.6–8.6ROR 8.3 · χ² 1,182 / p 2e-259 | 7.4 EB05 6.6 · IC025 +2.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site urticaria | 15 | 6.8 4.1–11.3ROR 6.9 · χ² 69 / p 5e-17 | 5.8 EB05 3.7 · IC025 +1.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eye disorder | 20 | 6.7 4.4–10.4ROR 6.8 · χ² 92 / p 4e-22 | 5.9 EB05 4.0 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Dry eye | 29 | 6.6 4.6–9.5ROR 6.7 · χ² 133 / p 5e-31 | 6.0 EB05 4.4 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eye swelling | 22 | 6.6 4.3–10.0ROR 6.6 · χ² 99 / p 2e-23 | 5.9 EB05 4.1 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Pruritus (itching) | 216 | 6.3 5.6–7.2ROR 7.0 · χ² 977 / p 9e-215 | 6.2 EB05 5.6 · IC025 +2.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Oral herpes | 11 | 6.2 3.5–11.3ROR 6.3 · χ² 43 / p 2e-11 | 5.1 EB05 3.0 · IC025 +1.3 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin exfoliation | 45 | 6.0 4.5–8.0ROR 6.1 · χ² 182 / p 8e-42 | 5.7 EB05 4.4 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Dry skin | 65 | 5.5 4.3–6.9ROR 5.6 · χ² 233 / p 5e-53 | 5.3 EB05 4.3 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Erythema (skin redness) | 91 | 4.9 4.0–6.0ROR 5.1 · χ² 281 / p 3e-63 | 4.8 EB05 4.0 · IC025 +1.9 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site reaction | 30 | 4.8 3.4–6.9ROR 4.9 · χ² 87 / p 4e-21 | 4.5 EB05 3.3 · IC025 +1.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site swelling | 29 | 4.2 2.9–6.1ROR 4.3 · χ² 68 / p 7e-17 | 4.0 EB05 2.9 · IC025 +1.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Therapeutic response decreased | 23 | 4.2 2.8–6.3ROR 4.2 · χ² 53 / p 1e-13 | 3.9 EB05 2.8 · IC025 +1.3 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Therapeutic response shortened | 12 | 4.2 2.4–7.3ROR 4.2 · χ² 26 / p 2e-7 | 3.7 EB05 2.3 · IC025 +0.9 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Underdose | 25 | 3.8 2.6–5.6ROR 3.8 · χ² 48 / p 2e-12 | 3.6 EB05 2.5 · IC025 +1.2 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Injection site rash | 10 | 3.6 2.0–6.7ROR 3.7 · χ² 17 / p 2e-5 | 3.2 EB05 1.9 · IC025 +0.6 | No label text to screen | – | no trial data cached |
| Injection site haemorrhage | 25 | 3.5 2.4–5.1ROR 3.5 · χ² 42 / p 5e-11 | 3.3 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin burning sensation | 22 | 3.4 2.3–5.2ROR 3.4 · χ² 35 / p 1e-9 | 3.2 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site erythema (redness where injected) | 36 | 3.2 2.3–4.4ROR 3.3 · χ² 53 / p 2e-13 | 3.1 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site pruritus | 19 | 3.2 2.0–4.9ROR 3.2 · χ² 26 / p 2e-7 | 3.0 EB05 2.0 · IC025 +0.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Incorrect dose administered | 54 | 2.7 2.0–3.4ROR 2.7 · χ² 54 / p 8e-14 | 2.6 EB05 2.1 · IC025 +0.9 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Injection site bruising | 15 | 2.1 1.3–3.5ROR 2.1 · χ² 8 / p 0.003 | 2.0 EB05 1.3 · IC025 +0.1 | No label text to screen | – | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Pruritus (itching) | 216 | 6.3 5.6–7.2ROR 7.0 · χ² 977 / p 9e-215 | 6.2 EB05 5.6 · IC025 +2.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site pain (pain where injected) | 207 | 7.5 6.6–8.6ROR 8.3 · χ² 1,182 / p 2e-259 | 7.4 EB05 6.6 · IC025 +2.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Dermatitis atopic | 131 | 29.0 24.6–34.2ROR 31.1 · χ² 3,514 / p <1e-300 | 28.8 EB05 24.9 · IC025 +4.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Conjunctivitis | 126 | 76.2 64.3–90.3ROR 81.5 · χ² 9,219 / p <1e-300 | 74.8 EB05 64.5 · IC025 +5.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eczema | 108 | 23.7 19.8–28.5ROR 25.1 · χ² 2,331 / p <1e-300 | 23.6 EB05 20.1 · IC025 +4.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Erythema (skin redness) | 91 | 4.9 4.0–6.0ROR 5.1 · χ² 281 / p 3e-63 | 4.8 EB05 4.0 · IC025 +1.9 3/3 methods agree | No label text to screen | – | no trial data cached |
| Dry skin | 65 | 5.5 4.3–6.9ROR 5.6 · χ² 233 / p 5e-53 | 5.3 EB05 4.3 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Incorrect dose administered | 54 | 2.7 2.0–3.4ROR 2.7 · χ² 54 / p 8e-14 | 2.6 EB05 2.1 · IC025 +0.9 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Ocular hyperaemia | 51 | 12.1 9.2–15.8ROR 12.4 · χ² 507 / p 2e-112 | 11.8 EB05 9.2 · IC025 +3.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin exfoliation | 45 | 6.0 4.5–8.0ROR 6.1 · χ² 182 / p 8e-42 | 5.7 EB05 4.4 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eye pruritus | 43 | 14.4 10.7–19.4ROR 14.7 · χ² 523 / p 4e-116 | 14.2 EB05 10.8 · IC025 +3.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Eye irritation | 39 | 7.7 5.7–10.5ROR 7.9 · χ² 222 / p 2e-50 | 7.2 EB05 5.5 · IC025 +2.3 3/3 methods agree | No label text to screen | – | no trial data cached |
| Incorrect dose administered by device | 38 | 16.5 12.1–22.7ROR 16.9 · χ² 539 / p 2e-119 | 16.3 EB05 12.3 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Injection site erythema (redness where injected) | 36 | 3.2 2.3–4.4ROR 3.3 · χ² 53 / p 2e-13 | 3.1 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site reaction | 30 | 4.8 3.4–6.9ROR 4.9 · χ² 87 / p 4e-21 | 4.5 EB05 3.3 · IC025 +1.6 3/3 methods agree | No label text to screen | – | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Lebrikizumab-Lbkz?
In FDA FAERS, the most frequently co-reported reaction terms for Lebrikizumab-Lbkz are pruritus, injection site pain, dermatitis atopic, conjunctivitis, eczema, erythema. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Lebrikizumab-Lbkz have an FDA boxed warning?
No validated FDA label could be retrieved for this product name, so this page cannot say.
Do FAERS signals prove that Lebrikizumab-Lbkz causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- No FDA label passed the name-validation check for this product string, so label-based screening was skipped
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 50 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.